In this Healio Video Perspective from the ASRS meeting, Eleonora M. Lad, MD, PhD, of Duke University Medical Center discusses findings from the phase 2 ARCHER trial investigating ANX007 for geographic atrophy.
The randomized, double-masked study enrolled 270 participants to receive either sham or ANX007 5 mg (Annexon Biosciences) monthly or every other month. ANX007 is a Fab antibody designed to selectively inhibit C1q to treat neurodegeneration, as Healio previously reported.
“This is a novel neuroprotective agent demonstrating benefits for visual acuity and photoreceptor structure in